1. Home
  2. DGLY vs BCDA Comparison

DGLY vs BCDA Comparison

Compare DGLY & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digital Ally Inc.

DGLY

Digital Ally Inc.

HOLD

Current Price

$0.88

Market Cap

1.3M

Sector

Technology

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.31

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGLY
BCDA
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DGLY
BCDA
Price
$0.88
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
137.7K
95.2K
Earning Date
12-29-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,097,965.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$1.00
52 Week High
$1,200.00
$3.20

Technical Indicators

Market Signals
Indicator
DGLY
BCDA
Relative Strength Index (RSI) 43.60 48.60
Support Level $0.64 $1.16
Resistance Level $1.41 $1.32
Average True Range (ATR) 0.08 0.08
MACD 0.02 0.00
Stochastic Oscillator 62.88 60.89

Price Performance

Historical Comparison
DGLY
BCDA

About DGLY Digital Ally Inc.

Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: